<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1660">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132000</url>
  </required_header>
  <id_info>
    <org_study_id>BCSCO002</org_study_id>
    <nct_id>NCT02132000</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fengxi Su</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of
      tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated
      derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought
      to compare the efficacy and tolerability of toremifene and tamoxifen therapy in
      premenopausal patients with operable,estrogen and/or progesterone receptor positive breast
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>survival outcomes: disease free survival</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects effects of therapies</measure>
    <time_frame>Follow-up period,up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the primary safety measures are Hepatic function and blood lipid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>follow-up period, up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events including hot flashes,  irregular menses and others.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3036</enrollment>
  <condition>Breast Cancer Patients in Premenopausal</condition>
  <condition>Estrogen and/or Progesterone Receptor Positive</condition>
  <arm_group>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tamoxifen,20mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>toremifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>toremifene,60mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>toremifene or tamoxifen</intervention_name>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_label>toremifene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Breast cancer

          -  Received standard treatment (chemotherapy, operation, or radiotherapy)

          -  premenopausal

          -  estrogen and/or progesterone receptor positive

        Exclusion Criteria:

          -  Metastatic tumors

          -  During pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Breast cancer center of Sun Yat-sen Memorial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaping yang, master</last_name>
      <phone>0086-020-34071145</phone>
      <email>yypapple1225@163.com</email>
    </contact>
    <investigator>
      <last_name>Fengxi Su, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weijuan Jia, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ran Gu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaping Yang, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 3, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Fengxi Su</investigator_full_name>
    <investigator_title>Chief of Breast cancer center in Sun Yat-Sen Memorial Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
